Intraarterial chemotherapy for osteosarcoma: Does the result really justify the effort?
The use of multiagent chemotherapy has led to improved survival for osteosarcoma patients. Infusion of cisplatin by the intraarterial route in order to devitalize the primary tumor more effectively has been advocated in this context. While systemic drug levels do not seem to be compromised by this regional approach, the envisioned increase in platinum content of osteosarcoma tissue has not been substantiated.
As far as clinical results are concerned, neither a comparison of various protocols including cisplatin by either intraarterial or intravenous application, nor the only controlled study dealing with the subject (COSS 86), were able to demonstrate a correlation between the route of cisplatin administration and tumor response to chemotherapy.
Therefore, the use of the intraarterial route for cisplatin treatment of osteosarcoma cannot be considered standard therapy but is still an investigational approach without proven benefits. In addition, the risk of side effects and the increased cost of this procedure should be considered before deciding to use intraarterial treatment for osteosarcoma.
KeywordsClin Oncol Osteosarcoma Patient Osteosarcoma Tissue Intraarterial Chemotherapy Platinum Level
Unable to display preview. Download preview PDF.
- 1.Bacci G, Avella M, Brach del Prevert A, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremities. Good response of the primary tumor after preoperative chemotherapy with high-dose methotrexate followed by cisplatinum and adriamycin. Preliminary results. Chemiotherapia 7:138–142, 1988.Google Scholar
- 2.Benjamin RS, Raymond AK, Carrasco CH, et al. Primary chemotherapy of osteosarcoma of the extremities with systemic adriamycin and intra-arterial cisplatinum. Proc Am Soc Clin Oncol 8, abstr. 1251, 1988.Google Scholar
- 4.Sierrasesumaga L, Bilbao J, Martin Algarra S, et al. Neoadjuvant chemotherapy with intraarterial (IA) cisplatinum (CDDP) and intravenous adriamycin (ADR) prior to limb sparing tumor resection plus chemotherapy in the treatment of osteosarcoma (OS). ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing, November 1–4, 1987, Madrid, Federation of European Cancer Societies, 1987, p 235.Google Scholar
- 5.Weiss A, Lachmann R, Berman J. (Intra-arterial preoperative chemotherapy for osteosarcoma. Proc Am Soc Clin Oncol 8:321, abstr. 1250), 1989.Google Scholar
- 6.Malawer M, Reaman G, Prienbat D, et al. Impact of a short course (2 cycles) of neoadjuvant chemotherapy with cisplatinum (DDP) and adriamycin (ADR) on the choice of surgical procedure for high-grade bone sarcomas of the extremities. Proc Am Soc Clin Oncol 8:320 (abstr. 1245), 1989.Google Scholar
- 10.Epelman S, Petrilli AS, Franco EL. Factors influencing survival of patients with nonmetastatic osteosarcoma treated with intra-arterial cisplatinum. Proc Am Soc Clin Oncol 6: abstr. 877, 1987.Google Scholar
- 11.Estrada J, Greenberg H, Walling AK, et al. Control of pelvic osteosarcoma (OS) with intraarterial (IA) chemotherapy and radiation therapy (XRT). Proc Am Soc Clin Oncol 7: abstr. 1075, 1988.Google Scholar
- 15.Bland KI, Kimura AK, Brenner DE, et al. A phase II study of the efficacy of diam-minedichloroplatinum (cisplatin) for the control of locally recurrent and intransit malignant melanoma of the extremities using tourniquet outflow-occlusion techniques. Ann Surg 209:73–80, 1989.PubMedCrossRefGoogle Scholar
- 17.Brock N, Pohl J. The basis of modern ifosfamide therapy. Introduction. Contrib Oncol 2:1–11, 1987.Google Scholar
- 22.Ratto GB, Mereu C, Vannuzi M, Fulco RA. Pharmacokinetics of cisplatin pulmonary artery infusion. Fourth International Congress on Advances in Regional Cancer Therapy, June 5–7, 1989, Berchtesgaden, FRG, Cyanamid-Lederle, Arzneimittel GmbH and Co., F10, 1989.Google Scholar
- 24.Mangues Baffaluy R. Pharmacokinetic advantage of the cisplatin intra-arterial administration over intravenous route: experimental and clinical study. Diss Abstr Int (C)50:282, 1989.Google Scholar
- 28.Jakowatz J, Snyder L, Ginn G, et al. Effect of route and schedule of cisplatin administration. Proc Am Soc Clin Oncol 8: abstr. 254, 1989.Google Scholar
- 29.Kishimoto S, Fukushima S, Hayashi Y, et al. Basic studies on optimal delivery rate of cisplatin. Gan Kagaku Ryohu 16:2788–2791, 1989.Google Scholar
- 33.Ruggieri P, Picci P, Marangolo M, et al. Neoadjuvant chemotherapy for osteosarcoma of the extremies (OS): preliminary results in 116 patients (PTS) treated preoperatively with methotrexate (MTX) (IV), cisplatinum (CDP) (IA) and adriamycin (ADM). Proc Am Soc Clin Oncol 9:310 (abstr. 1199), 1990.Google Scholar
- 35.Brunat-Mentigny M, Demaille MC, Quitana E, et al. The reproduction in France of Rosen’s protocol for osteosarcomas. Bull Cancer (Paris) 75:201–206, 1988.Google Scholar
- 36.Kalifa C, Mlika N, Dubousset J, et al. Experience with protocol T10 in the pediatric service at the Gustave-Roussy institute. Bull Cancer (Paris) 75:207–211, 1988.Google Scholar
- 37.Solheim OP. Adjuvant chemotherapy in patients with osteosarcoma. ECCO-4. Fourth European Conference on Clinical Oncology and Cancer Nursing, November 1–4, 1987, Madrid, Federation of European Cancer Societies, 1987, p 236.Google Scholar
- 38.Provisor A, Nachman J, Krailo M, et al. Treatment of non-metastatic osteosarcoma (OS) of the extremities with pre-and post-operative chemotherapy. Proc Am Soc Clin Oncol 6:217, 1987.Google Scholar
- 39.Green DM, Brecher ML, Douglass HO Jr., et al. The treatment of pediatric patients with osteosarcoma of an extremity. Does pre-operative intra-arterial chemotherapy affect prognosis? Proc Am Assoc Cancer Res 28:219, 1987.Google Scholar
- 40.Eilber FR, Giuliano AE, Huth JF, et al. Intravenous (IV) versus intraarterial (IA) adriamycin, 2800r radiation and surgical excision for extremely soft tissue sarcomas: a randomized prospective trial. Proc Am Soc Clin Oncol 9:309 (abstr. 1194), 1990.Google Scholar